Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

• Published in: Journal of inflammation (London, England) England), 2020-05, Vol.17 (1), p.19-19, Article 19
• Main Authors: Jiang, Rongmeng, Han, Bing, Song, Meihua, Xue, Bing, Zhang, Yongxiang, Ding, Yanyan, Chen, Jin, Zhu, Jing, Liu, Jianhua, Nie, Qingrong, Han, Xuefeng, Jin, Xiuhong, Shan, Xiaoyin, Guo, Weian, Zhang, Erming, Zhang, Zuoqing, Zhang, Changhong, Zhang, Jie, Wang, Baozeng, Dong, Shuwen, Li, Jiandong, Li, Xiaoguang, Li, Xingwang
• Format: Article
• Language: English
• Subjects: Adenoviruses; Aerosol inhalation; Bacterial infections; Blood pressure; Body temperature; Clinical medicine; Clinical trial; Clinical trials; Coronaviruses; Disease; Double-blind studies; Enrollments; Influenza; Inhalation; Injection; Interferon; Middle East respiratory syndrome; Noninfluenza viral pneumonia; Pain; Pathogens; Patients; Pharmaceuticals; Pneumonia; Recombinant human interferon α1b; Respiration; Respiratory diseases; Respiratory syncytial virus; Response rates; Statistical analysis; Streptococcus infections; Viral infections; Viruses
• ISSN: 1476-9255; 1476-9255
• DOI: 10.1186/s12950-020-00249-1

To investigate the efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia. One hundred sixty-four patients with noninfluenza viral pneumonia were divided into IFNα1b and control groups. The IFNα1b group received routine treatment + aerosol inhalation of recombinant human IFNα1b injection (50 μg × 2 injections, bid). The control group received routine treatment + IFN analog (two injections, bid). Overall response rate (ORR) of five kinds clinical symptoms. Further outcomes were daily average score and the response rate of each of the symptoms above. A total of 163 patients were included in the full analysis set (FAS) and 151 patients were included in the per-protocol set (PPS). After 7 days of treatment, ORR of clinical symptoms was higher in IFNα1b group than that in control group for both the FAS and PPS. Moreover, after 7 days of treatment, the daily score of three efficacy indexes including expectoration, respiratory rate, and pulmonary rales were improved. The ORRs for expectoration and pulmonary rales were higher in the IFNα1b group than in the control group (   0.05). The incidence of adverse events was 6.5% (  = 5) in IFNα1b group and 3.5% (  = 3) in control group (  > 0.05). Aerosol inhalation of recombinant human IFNα1b is safe and it can improve the clinical symptoms of noninfluenza viral pneumonia.